Replimune Group, Inc. (REPL): Price and Financial Metrics
GET POWR RATINGS... FREE!
REPL Stock Price Chart Interactive Chart >
REPL Price/Volume Stats
|Current price||$20.32||52-week high||$30.89|
|Prev. close||$19.98||52-week low||$13.05|
|Day high||$20.40||Avg. volume||306,572|
|50-day MA||$18.46||Dividend yield||N/A|
|200-day MA||$17.73||Market Cap||1.01B|
Replimune Group, Inc. (REPL) Company Bio
Replimune Ltd. develops oncolytic immunotherapies for the treatment of cancer. It is developing various proprietary products intended to enhance the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The company was founded in 2015 is based in Abingdon, the United Kingdom.
Most Popular Stories View All
REPL Latest News Stream
|Loading, please wait...|
REPL Latest Social Stream
View Full REPL Social Stream
Latest REPL News From Around the Web
Below are the latest news stories about REPLIMUNE GROUP INC that investors may wish to consider to help them evaluate REPL as an investment opportunity.
WOBURN, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY on Thursday, December 1, 2022 at 1:00 PM ET. About Replimune Replimune Group, Inc., headqu
Event to begin at 8:00 AM ETWOBURN, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team will host an investor event to provide a data update that will include preliminary data from the six-month follow-up of the first 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combined with
BMO Capital analyst Evan Seigerman maintained a Buy rating on Replimune Group (REPL - Research Report) today and set a price target of $40.00. The company's shares opened today at $17.74.Seigerman covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Regeneron, and Bristol Myers. According to TipRanks, Seigerman has an average return of 6.3% and a 53.85% success rate on recommended stocks. Currently, the analyst consensus on Replimune Group is a Strong Buy with an average price target of $38.80, which is an 118.71% upside from current levels. In a report released on November 4, H.C.
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Horizon Therapeutics (HZNP – Research Report), Crispr Therapeutics AG (CRSP – Research Report) and Replimune Group (REPL – Research Report) with bullish sentiments. Horizon Therapeutics (HZNP) BMO Capital analyst Gary Nachman maintained a Buy rating on Horizon Therapeutics today and set a price target of $117.00. The company's shares closed last Thursday at $71.92. According to TipRanks.
Completed enrollment in the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC); primary analysis data expected to be released in H1 2023 Six-month follow-up data from the first 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combined with Opdivo® (nivolumab) in anti-PD1 failed melanoma expected by year end An update on the RP2/3 development program remains on track to be provided by year end Completed $200 million term-loan tha
REPL Price Returns